

PPRI Advisory Board Tasks and Procedures

For the 3rd term PPRI Advisory Board (2026 – 2030)

Rationale and background

In 2005, a network of competent authorities responsible for pharmaceutical pricing and reimbursement (“PPRI network”) was established. With the financial support of the European Commission / EU Health Programme and the Austrian Federal Ministry of Health, Family and Youth, several deliverables (e.g. PPRI Pharma Profiles, indicators, comparative report, glossary) were produced for and with the members of the PPRI network. When the European Commission co-funding for the PPRI project ended in 2007, the PPRI network continued and developed into a **sustainable and voluntary cross-country collaboration of public authorities**, characterised by its informal character and the commitment of its members. The Austrian Ministry of Labour, Social Affairs, Health, Care and Consumer Protection supports the activities of the PPRI Secretariat to manage the PPRI network. The Secretariat is hosted by the Pharmacoeconomics Department of the Austrian National Public Health Institute in Vienna, Austria (the Pharmacoeconomics Department has been designated as WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies). The PPRI Secretariat acts as Secretariat of the PPRI Advisory Board.

Today, PPRI stands for **evidence-based information sharing and collection of data in the field of pricing and reimbursement of medicines as well as of medical devices** (a sub-group dedicated to medical devices was established in 2018). This includes data analysis and interpretation, and the transfer of knowledge to policymakers (“information brokerage” through capacity-building and dissemination). The PPRI network is at the heart of PPRI: this informal network aims to encourage and promote an exchange of information and experience about pharmaceutical policies among the PPRI network members based on shared values such as solidarity and equity, supported by scientific evidence as well as a common understanding and language on pharmaceutical issues.

Role and general objectives of the PPRI Advisory Board

The PPRI Advisory Board was **established in 2017 to provide advice and guidance to the PPRI Secretariat** in its vision, management and performance of PPRI-related activities. It aims to promote information exchange between representatives of international and national authorities and agencies working in pharmaceutical policy (in particular in the areas of pharmaceutical pricing and reimbursement).

Since the PPRI network is an informal structure, based on the commitment and voluntary contributions of its members, the PPRI Advisory Board is also set up in an **informal** way. No decision-making or voting takes place. Participation in the Advisory Board does not constitute official representation of the members’ institutions, and the views do not necessarily represent the position of the institutions.

Objectives and tasks of PPRI Advisory Board

- Providing **background information from the institutions** and, if necessary, **advice about strategic directions** of the PPRI network and the activities of the PPRI Secretariat, including thematic work on pharmaceutical pricing and reimbursement;
- **Informing about** similar (national and international) **initiatives** to allow the PPRI Secretariat to align and coordinate its activities in the international context;

- **Commenting on PPRI work plans** for the coming year(s) and supporting the development of and shaping future PPRI activities;
- Fostering **collaboration with PPRI network members** and identifying possible new members eligible for the PPRI network and providing strategic advice regarding membership development;
- Building **bridges to external parties** of relevance for PPRI (including helping identify possible sponsors for research activities);
- Providing **comments to the PPRI Secretariat about its work** and the progress of the PPRI network, including discussions of learning of PPRI evaluations;
- **Supporting communication and dissemination activities** of the PPRI Secretariat and the PPRI network (including and in particular to their own institutions), thus contributing to a reduction in redundancies (e.g. avoiding duplication of similar projects) as well as improved visibility;
- *For outgoing members of a previous term in a transition year (e.g., year 2026): Support and guidance to incoming Advisory Board members.*

Membership

Membership in the PPRI network is a prerequisite for serving on the PPRI Advisory Board. Membership in the Advisory Board is institution-based. Membership is limited to **one person per institution**, but Board members are allowed to nominate **1-2 deputy member(s)** to attend PPRI Advisory Board meetings on their behalf. PPRI Deputy Advisory Board members are included in all correspondence pertaining to Advisory Board matters.

The PPRI Secretariat is responsible for inviting members to the PPRI Advisory Board. Only institutions that have been PPRI network members for at least two years are eligible. In selecting Advisory Board members, the PPRI Secretariat aims to ensure a balanced composition, drawing from international organisations, European institutions and national authorities. For national institutions in particular, attention is given to diversity in terms of geographical region, country income level and size, as well as the organisation of the health care and pharmaceutical and medical device system.

Membership terms

The PPRI Advisory Board is based on a rotation principle. A membership term is intended to last for four years and can be extended. Extensions of membership terms may be offered based on the member institution's ongoing engagement, contribution, and the overall balance of Advisory Board composition.

The first membership term lasted from 2017 until 2020, and the second term from 2021 until 2025. The third term is scheduled from 2026 until 2030. To ensure a good transition, PPRI Advisory Board members of the second term will remain on the Advisory Board until the end of 2026.

As of 2026, the members of the PPRI Advisory Board are:

- Austrian Ministry of Labour, Social Affairs, Health, Care and Consumer Protection (funder of the PPRI Secretariat)
- European and international institutions:
 - European Commission, DG SANTÉ
 - OECD
 - WHO Headquarters
 - WHO Regional Office for Europe

- PPRI member country's institutions:

Members of the 2nd term, starting in 2021; outgoing at the end of 2026

- Patented Medicine Prices Review Board (PMPRB), Canada
- Estonian Health Insurance Fund, Estonia
- National Organization for the Provision of Healthcare Services (EOPPY), Greece
- National Authority of Medicines and Health Products, I.P. (INFARMED), Portugal
- Dental and Pharmaceutical Benefits Agency (TLV), Sweden

Members of the 3rd term (2026-2030)

- Brazilian Agency of Health Surveillance (Anvisa), Brazil
- Caisse nationale de l'Assurance Maladie (CNAM), France
- National Association of Statutory Health Insurance Funds (GKV-Spitzenverband), Germany
- Ministry of Health of the Republic of Lithuania
- Federal Office of Public Health (FOPH), Switzerland

Funding of the activities of the Advisory Board

Membership to the PPRI Advisory Board is on a **voluntary basis** and in an **honorary capacity**. Financial costs incurred by members of the Advisory Board to participate in the Advisory Board meetings shall be covered by the members' parent organisations. Apart from coverage of these costs, participation in the **Advisory Board does not commit the member institution to any financial or other obligation**.

Transparency and conflict of interest

The Tasks and Procedures document of the PPRI Advisory Board is published at the website of the Pharmacoeconomics Department of GÖG (ppri.goeg.at). The organisations of the PPRI Advisory Board members will also be published on the PPRI website. All members must sign a Declaration of Interest form.

Outcomes of the discussions will be presented to the PPRI network at PPRI network meetings unless confidentiality has been agreed among PPRI Advisory Board members. Documents distributed at Advisory Board Meetings may not be forwarded to other parties unless decided otherwise.

Operational issues

- One to two **face-to-face meetings** per year (alternatively: virtual meetings) at convenient dates (close to or at PPRI network meetings; notifications will be sent by the Secretariat of the PPRI Advisory Board in due time before the meetings, at least 2 weeks before);
- **Ad-hoc video conferences**;
- The Secretariat is responsible for organising the meetings (location, facilities), providing the agenda and relevant documents, for the meeting documentation (minutes) and a follow-up of the decisions. Members of the Advisory Board may at all times contribute to the preparation of the meetings.

Commitment and expectations

The members of the PPRI Advisory Board are expected to:

- ensure, as far as possible, **participation** of a representative in the PPRI Advisory Board meetings;
- **support** achieving the objectives as mentioned above;
- **notify** members of the PPRI Advisory Board if any matter arises which may be deemed to affect the development of the PPRI network or the PPRI Advisory Board.

Members of the PPRI Advisory Board can expect:

- that each member will be provided with complete, accurate and meaningful **information** in a timely manner by the PPRI Secretariat;
- to be given reasonable **time** to prepare for the PPRI Advisory Board meetings and to provide comments;
- to be **alerted** to potential risks and issues that could impact PPRI, as they arise;
- open and honest **discussions**.

Updates

This document can be adapted upon mutual agreement of the PPRI Advisory Board.

Version as of 13 May 2026